Larry A. Greenbaum
A5038495729- Renal Diseases and Glomerulopathies
- Complement system in diseases
- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Adolescent and Pediatric Healthcare
- Adenosine and Purinergic Signaling
- Renal Transplantation Outcomes and Treatments
- Pediatric Urology and Nephrology Studies
- Electrolyte and hormonal disorders
- Iron Metabolism and Disorders
- Childhood Cancer Survivors' Quality of Life
- Neonatal Health and Biochemistry
- Pregnancy and Medication Impact
- Biomedical Research and Pathophysiology
- Renal function and acid-base balance
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Ion Transport and Channel Regulation
- Autoimmune Bullous Skin Diseases
- Erythropoietin and Anemia Treatment
- Renal and Vascular Pathologies
- Urological Disorders and Treatments
- Systemic Lupus Erythematosus Research
- Renal and related cancers
- Parathyroid Disorders and Treatments
- Vitamin C and Antioxidants Research
Children's Healthcare of Atlanta
2016-2025
Emory University
2016-2025
Jeju National University
2020-2023
National University College
2023
New Generation University College
2023
Jeju National University Hospital
2023
National Center for Global Health and Medicine
2020
Kitasato University
2020
Tohoku Medical Megabank Organization
2020
Tohoku University
2020
Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels hematologic measures but does not treat the underlying systemic disease.
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal other end-organ damage. We originally conducted two phase 2 studies (26 weeks 1 year) evaluating eculizumab, terminal complement inhibitor, in patients with progressing TMA (trial 1) those long duration of aHUS chronic kidney 2). The current analysis assessed outcomes after years (median eculizumab...
The therapeutic approach to childhood nephrotic syndrome is based on a series of studies that began with an international collaborative effort sponsored by the International Study Kidney Disease in Children 1967. characteristics children presenting have changed over recent decades greater frequency challenging condition focal segmental glomerulosclerosis and prevalence obesity diabetes mellitus, which may be resistant glucocorticoids former exacerbated long-term glucocorticoid therapy latter...
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults retrospective data children, eculizumab, a terminal inhibitor, approved for aHUS treatment. Here we prospectively evaluated efficacy safety of weight-based dosing eculizumab eligible pediatric patients with an open-label phase II study. The primary end point was...
<h3>Background</h3> Children admitted to the hospital with urinary tract infections (UTIs) receive empirical antibiotic therapy. There is limited information on bacterial resistance commonly prescribed intravenous antibiotics or risk factors for increased in these patients. <h3>Objectives</h3> To determine pattern children UTIs, and if history of UTI, prophylaxis, vesicoureteral reflux increases resistant organisms. <h3>Design/Methods</h3> We reviewed all cases UTI up 18 years age who were...
Steroid-sensitive nephrotic syndrome (SSNS) accounts for >80% of cases in childhood. However, the etiology and pathogenesis SSNS remain obscure. Hypothesizing that coding variation may underlie risk, we conducted an exome array association study SSNS. We enrolled a discovery set 363 persons (214 South Asian children with 149 controls) genotyped them using Illumina HumanExome Beadchip. Four common single nucleotide polymorphisms (SNPs) HLA-DQA1 HLA-DQB1 (rs1129740, rs9273349, rs1071630,...
Background and objectives: Children with chronic kidney disease (CKD) have an increased risk of progression to ESRD. There is a need identify treatments slow the CKD, yet there are limited data regarding clinical factors that may be suitable targets progression. Design, setting, participants, & measurements: We performed retrospective cohort study using North American Pediatric Renal Trials Cooperative Studies CKD database. were 4166 pediatric subjects stages II IV. Disease was defined as...
End-stage renal disease (ESRD) is associated with uremia and increased systemic inflammation. Alteration of the intestinal microbiota may facilitate translocation endotoxins into circulation leading to We hypothesized that children ESRD have an altered serum levels bacterially derived uremic toxins.Four groups subjects were recruited: peritoneal dialysis (PD), hemodialysis (HD), post-kidney transplant healthy controls. Stool bacterial composition was assessed by pyrosequencing analysis 16S...
There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of aHUS treated eculizumab.Patients who participated any five parent eculizumab trials and received at least one infusion were eligible for enrollment a follow-up study. Rates thrombotic microangiopathy (TMA) manifestations off versus on evaluated. Additional endpoints included change...
Dysregulated complement activation is likely the primary driver of disease in C3 glomerulopathy (C3G) and contributes to other complement-mediated diseases, including immunoglobulin A nephropathy (IgAN), lupus nephritis (LN), membranous (PMN). No inhibitors are proven halt progression these diseases. Pegcetacoplan, a targeted C3b inhibitor, may mitigate kidney damage C3G glomerular diseases which have pathogenic role.This open-label, phase 2, 48-week study evaluated preliminary efficacy...
Tolvaptan slows expansion of kidney volume and function decline in adults with autosomal dominant polycystic disease (ADPKD). Progression during childhood could be treated before irreversible damage occurs, but trial data are lacking. We evaluated the safety efficacy tolvaptan children/adolescents ADPKD.
Although prevalence of traditional cardiovascular risk factors (CVRF) has been described in children with CKD, the frequency which these CVRF occur concomitantly and clinical characteristics associated multiple are unknown. This study determined Chronic Kidney Disease Children study.Using cross-sectional data from first follow-up visits, we four CVRF: hypertension (casual BP >95(th) percentile or self-reported concurrent use anti-hypertensive medication), dyslipidemia (triglycerides >130...
Immediate-release cysteamine bitartrate (Cystagon; Mylan Pharmaceuticals, Canonsburg, PA) may prevent or delay kidney transplantation and other serious outcomes in patients with cystinosis, but has never been subjected to a prospective clinical trial. Cystagon efficacy requires strict lifelong dosing every 6 hours. Such schedule Cystagon-associated side effects are often cited by as reasons for nonadherence.This open-label, randomized, controlled, crossover trial was powered show that new...
Recurrence of atypical hemolytic uremic syndrome (aHUS) in renal allografts is common, leading to dialysis and graft failure. Pretransplant versus posttransplant initiation eculizumab treatment patients with aHUS has not been rigorously investigated. We hypothesized pretransplant would reduce incidence posttransplant.Of enrolled the Global Registry (n = 1549), 344 had ≥1 kidney transplant. Of these, 188 received eculizumab. Eighty-eight (47%) were diagnosed before, during, their most recent...
Atypical hemolytic uremic syndrome (aHUS) is a rare, genetically-mediated systemic disease most often caused by chronic, uncontrolled complement activation that leads to thrombotic microangiopathy (TMA) and renal other end-organ damage. The global aHUS Registry, initiated in April 2012, an observational, noninterventional, multicenter registry designed collect demographic characteristics, medical history, treatment effectiveness safety outcomes data for patients. Registry will operate...